These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29634425)

  • 1. Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment.
    Kowalczyk WJ; Moran LM; Bertz JW; Phillips KA; Ghitza UE; Vahabzadeh M; Lin JL; Epstein DH; Preston KL
    Am J Drug Alcohol Abuse; 2018; 44(5):502-511. PubMed ID: 29634425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.
    Kowalczyk WJ; Phillips KA; Jobes ML; Kennedy AP; Ghitza UE; Agage DA; Schmittner JP; Epstein DH; Preston KL
    Am J Psychiatry; 2015 Aug; 172(8):760-7. PubMed ID: 25783757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stress, craving and mood as predictors of early dropout from opioid agonist therapy.
    Panlilio LV; Stull SW; Kowalczyk WJ; Phillips KA; Schroeder JR; Bertz JW; Vahabzadeh M; Lin JL; Mezghanni M; Nunes EV; Epstein DH; Preston KL
    Drug Alcohol Depend; 2019 Sep; 202():200-208. PubMed ID: 31357121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients.
    Kowalczyk WJ; Bertz JW; Moran LM; Phillips KA; Ghitza UE; Epstein DH; Preston KL
    J Addict Med; 2017; 11(6):454-460. PubMed ID: 28759482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond abstinence and relapse II: momentary relationships between stress, craving, and lapse within clusters of patients with similar patterns of drug use.
    Panlilio LV; Stull SW; Bertz JW; Burgess-Hull AJ; Lanza ST; Curtis BL; Phillips KA; Epstein DH; Preston KL
    Psychopharmacology (Berl); 2021 Jun; 238(6):1513-1529. PubMed ID: 33558983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial.
    Garland EL; Hanley AW; Kline A; Cooperman NA
    Drug Alcohol Depend; 2019 Oct; 203():61-65. PubMed ID: 31404850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Before and after: craving, mood, and background stress in the hours surrounding drug use and stressful events in patients with opioid-use disorder.
    Preston KL; Kowalczyk WJ; Phillips KA; Jobes ML; Vahabzadeh M; Lin JL; Mezghanni M; Epstein DH
    Psychopharmacology (Berl); 2018 Sep; 235(9):2713-2723. PubMed ID: 29980821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Craving mediates the association between momentary pain and illicit opioid use during treatment for opioid-use disorder: an ecological momentary assessment study.
    Mun CJ; Finan PH; Epstein DH; Kowalczyk WJ; Agage D; Letzen JE; Phillips KA; Preston KL
    Addiction; 2021 Jul; 116(7):1794-1804. PubMed ID: 33220102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
    Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
    JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
    Rosenthal RN; Ling W; Casadonte P; Vocci F; Bailey GL; Kampman K; Patkar A; Chavoustie S; Blasey C; Sigmon S; Beebe KL
    Addiction; 2013 Dec; 108(12):2141-9. PubMed ID: 23919595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine for managing opioid withdrawal.
    Gowing L; Ali R; White JM; Mbewe D
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
    Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
    JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
    Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
    JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone and buprenorphine combination in the treatment of opioid dependence.
    Gerra G; Fantoma A; Zaimovic A
    J Psychopharmacol; 2006 Nov; 20(6):806-14. PubMed ID: 16401652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.
    Ling W; Casadonte P; Bigelow G; Kampman KM; Patkar A; Bailey GL; Rosenthal RN; Beebe KL
    JAMA; 2010 Oct; 304(14):1576-83. PubMed ID: 20940383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.